NASDAQ:CERS - Cerus Stock Price, Forecast & News

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus Co. (NASDAQ:CERS) released its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.01. The biotechnology company earned $18 million during the quarter, compared to the consensus estimate of $17.69 million. Cerus had a negative net margin of 95.44% and a negative return on equity of 109.08%. The business's revenue for the quarter was up 16.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.11) earnings per share. View Cerus' Earnings History.

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Cerus.

Cerus issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $110.77 million.

3 brokers have issued 12 month price targets for Cerus' shares. Their forecasts range from $7.00 to $8.00. On average, they expect Cerus' stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Price Targets for Cerus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.

Media headlines about CERS stock have trended extremely negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cerus earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Cerus.

Some companies that are related to Cerus include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Anika Therapeutics (ANIK), Antares Pharma (ATRS), OraSure Technologies (OSUR) and RTI Surgical (RTIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK), Celldex Therapeutics (CLDX), Omeros (OMER), Grayscale Bitcoin Trust (Btc) (GBTC) and Aduro BioTech (ADRO).

Cerus' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.96%), Nikko Asset Management Americas Inc. (6.15%), ARK Investment Management LLC (6.71%), State Street Corp (2.52%), Peregrine Capital Management LLC (1.70%) and Senvest Management LLC (1.26%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

CERS stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, King Luther Capital Management Corp, Bank of America Corp DE, Bamco Inc. NY, Principal Financial Group Inc., Senvest Management LLC, New York State Common Retirement Fund and UBS Group AG. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson and William Mariner Greenman. View Insider Buying and Selling for Cerus.

CERS stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., ARK Investment Management LLC, State Street Corp, Peregrine Capital Management LLC, Jacobs Levy Equity Management Inc. and Millrace Asset Group Inc.. Company insiders that have bought Cerus stock in the last two years include Laurence M Corash, Timothy L Moore and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CERS stock can currently be purchased for approximately $5.16.

Cerus has a market capitalization of $819.82 million and generates $74.65 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.

The official website for Cerus is http://www.cerus.com/.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]